Biotech · Private company
EpiDestiny, Inc.
Track this companyFree. Adds EpiDestiny, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials52 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- DecitabinePhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- NicotinamidePhase 1 · Sickle Cell DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- TetrahydrouridinePhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)PHASE1 · RECRUITING · started Jun 3, 2025ClinicalTrials.gov NCT07006025 · fetched Nov 12, 2026
- To Study the Oral Bioavailability of a New Combination Formation of Decitabine and Tetrahydrouridine in Healthy MalesPHASE1 · COMPLETED · started Mar 24, 2023ClinicalTrials.gov NCT05816356 · fetched Nov 12, 2026
- A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell DiseasePHASE1 · RECRUITING · started Jan 24, 2020ClinicalTrials.gov NCT04055818 · fetched Nov 12, 2026
- Effect of Food on the Pharmacokinetics of Decitabine/Tetrahydrouridine Combination Capsules in Healthy Adult SubjectsPHASE1 · COMPLETED · started Oct 8, 2019ClinicalTrials.gov NCT04086238 · fetched Nov 12, 2026
- Randomized, Single-dose, Crossover Study of 4 Decitabine and Tetrahydrouridine (EPI01) Formulations in Healthy SubjectsPHASE1 · COMPLETED · started Apr 3, 2019ClinicalTrials.gov NCT03828084 · fetched Nov 12, 2026